Evidence map›Paper›PMID 41667510›Full record

ArticleNature communications2026

Chemoenzymatic synthesis of pentalenolactones via stereoselective Riley oxidation by engineered P450

Yaoyao Xu, Kaifeng Zhang, Quanzhen Lv, Jinxin Wang, Jian Li

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yaoyao XuFrontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs and Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China.ORCID 0009-0005-8898-6509
Kaifeng ZhangThe Division of Biosciences, UCL Faculty of Life Sciences, University College London, London, UK.
Quanzhen LvThe Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Naval Medical University, Shanghai, China.ORCID 0000-0003-2045-6091
Jinxin WangThe Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Naval Medical University, Shanghai, China. jxwang2013@126.com.ORCID 0000-0001-9561-7633
Jian LiFrontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs and Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China. jianlizcz@sjtu.edu.cn.ORCID 0000-0003-4461-6686

Funding

National Key R&D Program of ChinaNational Natural Science Foundation of China (National Science Foundation of China) 22371184National Science Foundation of China | Young Scientists Fund 22371184
6 · The paper itself

Abstract

Riley oxidation is a powerful method for introducing oxygen functionality but typically relies on toxic reagents and generally lacks enantiocontrol. This limitation has historically restricted the utility of this transformation for the direct asymmetric construction of complex scaffolds. Here, we show that fusion library screening and directed evolution enable the highly enantio- and diastereoselective Riley-type oxidation of a cis-diquinane substrate catalyzed by engineered P450

Indexed as

Bacterial ProteinsCytochrome P-450 Enzyme SystemLactonesNADPH-Ferrihemoprotein ReductaseProtein EngineeringOxidation-ReductionStereoisomerismBacterial ProteinsCytochrome P-450 Enzyme Systemflavocytochrome P450 BM3 monoxygenasesLactonesNADPH-Ferrihemoprotein Reductase

Identifiers

PMID41667510
PMCPMC13000223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.